the collaboration on neurological diseases (hopefully no platelet issue yet) may lead to a corporate transaction. This is where BIIB is going as they are spinning off their hemophilia franchise.
The most interesting piece of data we saw was Nimbus’ NDI-010976. Gilead acquired the rights to the drug recently for $400 million upfront and $800 million in potential milestones. We now see why Gilead wanted the drug. NDI-010976 is an acetyl-CoA carboxylase (ACC) inhibitor. ACC is a critical enzyme in fatty acid metabolism. The drug blocks fatty acid synthesis, lowers tissue triglycerides, and increases fatty acid oxidation and insulin sensitivity. In a dose-finding study, Nimbus was able to inhibit de novo lipogenesis in a dose-dependent fashion. At the high dose (200 mg), the drug completely blocked de novo lipogenesis. In other words, it succeeded in taking the fat out of the fatty liver. If there are no untoward side effects in larger and longer studies, this approach promises to be a potent mechanism of action in reversing fatty liver (NAFLD), and potentially halting the disease progression from NAFLD to NASH to cirrhosis. The frustration in the field has been that the drugs currently in late-stage trials for NASH – be they OCA (ICPT) or dual PPAR (GNFT.PA) – are limited in efficacy This ACC inhibitor may be different.
lol do you really think your posts can control the share price?
I have an idea, use your left hand and pretend it's someone else.
keep dreaming... its down
stock looks like a secondary coming
you sound like a real windbag. btw, looks like no news for a few weeks. they are appearing at the needham conf. you don't announce big news before one brokerage conf.
yes they have cash BUT they're spending it they have to raise cash this year---can't wait ill 2017
they need a capital raise but can't or won't sell stock at these prices
company will be put up for sale
I agree that a buyout is possible.
Diamond Foods was a disaster after the accounting scandal but it got acquired.
Healthy snacks are hot and this micro market cap would make a buyout easy.
Also the product line would make a good fit for lots of companies.
I own BGS and they bought Green Giant and Pirate's Bounty.
you should seek professional help. you are beyond neurotic you may be psychotic
most likely true.........but
has nothing to do with fundamentals...just market action
these are open end mutual funds.........mkt goes down-holders redeem......portfolio managers have to raise cash